Genmab — Maj 2018
-
Dette har nok aldrig været nævnt i JNJs præsentationer
-
Bortset fra det så er overskriften på nyheden strengt taget lidt forkert. De skriver jo at "has contacted its partner companies conducting daratumumab and anti-PD-(L)1 combination studies to discuss ceasing enrollment and dosing of the combination while the data is being further investigated."
-
Sukkeralf- for 2018 mener jeg tv data er de vigtigste. Fordi 1) 50% ejerandel og 2) hvis det ikke lykkes, så er det omkostninger down the drain
-
-
MAIA mà selvfølgelig under ingen omstændigheder skuffe
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind